Manufacturing· June 14, 2026 · 11 min read
Topic
Medicare Part B
Medicare Part B drug reimbursement, ASP methodology, buy-and-bill, J-codes, and provider-administered drug billing.
Policy· June 9, 2026 · 12 min read
IRA Medicare drug negotiation third cycle: 15 drugs selected for 2028
Pricing & Access· June 1, 2026 · 12 min read
IRA Part B drug negotiation: provider reimbursement risk under the buy-and-bill model
Pricing & Access· May 31, 2026 · 13 min read
Retina buy-and-bill inventory risk when payer preference changes
By Ran Chen#Anti-VEGF#Ophthalmology#Buy and Bill
Pricing & Access· May 29, 2026 · 10 min read
Tecentriq Hybreza bladder cancer MRD access guide
By Ran Chen#Oncology#PD-L1#Companion Diagnostic
Pricing & Access· May 27, 2026 · 11 min read
Leqembi vs Kisunla access guide for anti-amyloid mAb coverage
Pricing & Access· May 27, 2026 · 10 min read
Spravato REMS and coverage guide for esketamine access
By Ran Chen#REMS#Prior Authorization#Coverage Access
Pricing & Access· May 22, 2026 · 12 min read
ASP lag after launch: why buy-and-bill economics can break in the first quarters
By Ran Chen#Medicare Part B#ASP#Buy and Bill
Pricing & Access· May 22, 2026 · 9 min read
J-code timing and interim billing risk for new buy-and-bill biologics
By Ran Chen#Medicare Part B#HCPCS#J-Code